Xiang Li, Jiang Peng, Zhan Changsen, Chen Zhongliang, Liu Xiaojun, Huang Xinming, Wang Shuping, Hu Yaohua, Zhang Weidong, Liu Runhui
School of Pharmacy, Second Military Medical University, Shanghai, 200433, PR China.
Mol Biosyst. 2012 Sep;8(9):2434-42. doi: 10.1039/c2mb25172h. Epub 2012 Jul 12.
A metabolomic approach based on liquid chromatography coupled with quadrupole time-of-flight detector (LC-Q-TOF/MS) was developed to investigate the therapeutic mechanism of a traditional Chinese medicine (TCM) formula Shexiang Baoxin Pill (SBP) and a multi-component medicine polypill (consisting of simvastatin (Sim), atenolol (Ate), ramipril (Ram), hydrochlorthiazide (Hyd) and aspirin (Asp), named as SARHA). Twenty-seven biomarkers were identified in the serum of MI rats. Thirteen related pathways and 4 main pathological processes including oxidative injury, energy metabolism dysfunction, amino acid metabolism dysfunction and inflammation are involved in MI development. Our study revealed that SBP showed better therapeutic effectiveness than the polypill on MI through regulation of the energy metabolism dysfunction, oxidative injury and inflammation. The combination agent polypill had only certain therapeutic effects on inhibiting oxidative injury and inflammation induced by MI. The reverse effect of the polypill on biomarkers related to MI was much better than mono-therapy groups.
基于液相色谱与四极杆飞行时间检测器联用（LC-Q-TOF/MS）的代谢组学方法被用于研究中药复方麝香保心丸（SBP）和一种多成分药物复方制剂（由辛伐他汀（Sim）、阿替洛尔（Ate）、雷米普利（Ram）、氢氯噻嗪（Hyd）和阿司匹林（Asp）组成，命名为SARHA）的治疗机制。在心肌梗死（MI）大鼠血清中鉴定出27种生物标志物。MI的发生涉及13条相关通路以及4个主要病理过程，包括氧化损伤、能量代谢功能障碍、氨基酸代谢功能障碍和炎症。我们的研究表明，SBP通过调节能量代谢功能障碍、氧化损伤和炎症，在MI治疗上比复方制剂表现出更好的疗效。该复方制剂组合药物对抑制MI诱导的氧化损伤和炎症仅有一定的治疗作用。该复方制剂对与MI相关生物标志物的反向作用比单药治疗组要好得多。
